Startupsby GlyphAltay Therapeutics
Active · Altay develops disease-modifying therapies targeting transcription…
Why it ranks
How the rank works- team of 6Team size · YC's directory+4.4
- went through YCProgram · this site+4
A sum of public facts, not a judgement and not investment advice.
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YC +1W20 | |
| Other | Active | YCW21 | |
| AI | Active | YCS19 | |
| Encepheal TherapeuticsShared: fda approved, small molecule, drug discoveryYC S19InactiveOther | Other | Inactive | YCS19 |
| Other | Active | YCW24 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YCW22 | |
| Other | Not stated | Plug and Play | |
| Other | Active | YCS18 | |
| Other | Acquired | YCW16 | |
| AI | Active | YCS20 |
Also from W20 in AI
All of W20About Altay Therapeutics
Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.
- YC batch
- W20 · Winter 2020
- Status, per YC
- Active
- Category
- AI
- Team size
- 6
- Location
- San Francisco, CA, USA; South San Francisco, CA, USA
- Checked
- 7h ago
YC tags: AI-powered Drug Discovery, Biotech, Therapeutics, Drug discovery
Altay Therapeutics: questions
Which YC batch was Altay Therapeutics in?
Altay Therapeutics was in Y Combinator's Winter 2020 batch (W20).
Is Altay Therapeutics still active?
Y Combinator lists Altay Therapeutics as active.
Where is Altay Therapeutics based?
Altay Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.